Cancer Drug Study Ignites Biotech Shares Days After Goldman Cut

(Bloomberg) -- Immunomedics Inc. shares more than doubled after a study of its breast cancer drug was stopped early on promising results.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.